lisinopril and Vitamin-D-Deficiency

lisinopril has been researched along with Vitamin-D-Deficiency* in 2 studies

Other Studies

2 other study(ies) available for lisinopril and Vitamin-D-Deficiency

Article	Year
Screening for Vitamin D Deficiency in Adults. American family physician, 2021, 11-01, Volume: 104, Issue:5 Topics: Antihypertensive Agents; Asymptomatic Diseases; Body Mass Index; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Lisinopril; Male; Mass Screening; Metformin; Middle Aged; Obesity; Patient Selection; Risk Assessment; Risk Factors; Vitamin D; Vitamin D Deficiency; Vitamins	2021
Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 128, Issue:1-2 Vitamin D deficiency is common in chronic kidney disease (CKD). Increased urinary loss of vitamin D binding protein (VDBP), the main transporter of 25-hydroxyvitamin D(3) in the circulation, has been postulated to contribute to vitamin D deficiency in proteinuria. To test this hypothesis we analyzed urinary and plasma levels of VDBP, 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) from proteinuric patients, before and after antiproteinuric interventions. We performed a post-hoc analysis of a clinical trial in CKD patients (n=13, creatinine clearance median 60 (range 25-177) ml/min) subjected to the following study periods: washout (no antiproteinuric treatment, 4 weeks), lisinopril 40mg QD (ACEi, 6 weeks), or indomethacin 75mg BID (NSAID, 4 weeks) in randomized sequence. Healthy subjects screened for donation (n=10) served as controls. Plasma and urine VDBP levels were measured by ELISA, 25-hydroxyvitamin D(3) levels by LC-MS and 1,25-dihydroxyvitamin D(3) levels by radioimmunoassay. In CKD patients urinary VDBP excretion was strongly increased (median (range) 5413 (155-211,027) μg/24h) as compared to healthy controls (64 (23-111) μg/24h, p<0.001). Both NSAID and ACEi significantly decreased urinary VDBP excretion, in proportion to proteinuria reduction. Plasma VDBP, 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) levels, however, were similar between patients and controls and not affected by antiproteinuric intervention. Urinary VDBP excretion is markedly increased in proteinuria and responds to antiproteinuric treatment. Urinary VDBP loss is not associated with plasma VDBP or vitamin D(3) levels, suggesting that urinary loss of VDBP does not affect vitamin D status. Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Indomethacin; Kidney Failure, Chronic; Lactones; Lisinopril; Male; Middle Aged; Proteinuria; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Sulfones; Vitamin D Deficiency; Vitamin D-Binding Protein	2012

Article

Year

Screening for Vitamin D Deficiency in Adults.

American family physician, 2021, 11-01, Volume: 104, Issue:5

Topics: Antihypertensive Agents; Asymptomatic Diseases; Body Mass Index; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Lisinopril; Male; Mass Screening; Metformin; Middle Aged; Obesity; Patient Selection; Risk Assessment; Risk Factors; Vitamin D; Vitamin D Deficiency; Vitamins

2021

Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease.

The Journal of steroid biochemistry and molecular biology, 2012, Volume: 128, Issue:1-2

Vitamin D deficiency is common in chronic kidney disease (CKD). Increased urinary loss of vitamin D binding protein (VDBP), the main transporter of 25-hydroxyvitamin D(3) in the circulation, has been postulated to contribute to vitamin D deficiency in proteinuria. To test this hypothesis we analyzed urinary and plasma levels of VDBP, 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) from proteinuric patients, before and after antiproteinuric interventions. We performed a post-hoc analysis of a clinical trial in CKD patients (n=13, creatinine clearance median 60 (range 25-177) ml/min) subjected to the following study periods: washout (no antiproteinuric treatment, 4 weeks), lisinopril 40mg QD (ACEi, 6 weeks), or indomethacin 75mg BID (NSAID, 4 weeks) in randomized sequence. Healthy subjects screened for donation (n=10) served as controls. Plasma and urine VDBP levels were measured by ELISA, 25-hydroxyvitamin D(3) levels by LC-MS and 1,25-dihydroxyvitamin D(3) levels by radioimmunoassay. In CKD patients urinary VDBP excretion was strongly increased (median (range) 5413 (155-211,027) μg/24h) as compared to healthy controls (64 (23-111) μg/24h, p<0.001). Both NSAID and ACEi significantly decreased urinary VDBP excretion, in proportion to proteinuria reduction. Plasma VDBP, 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) levels, however, were similar between patients and controls and not affected by antiproteinuric intervention. Urinary VDBP excretion is markedly increased in proteinuria and responds to antiproteinuric treatment. Urinary VDBP loss is not associated with plasma VDBP or vitamin D(3) levels, suggesting that urinary loss of VDBP does not affect vitamin D status.

Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Indomethacin; Kidney Failure, Chronic; Lactones; Lisinopril; Male; Middle Aged; Proteinuria; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Sulfones; Vitamin D Deficiency; Vitamin D-Binding Protein

2012